Korsana Biosciences, Inc. (KRSA)
KRSANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$31.11
-0.3000 (-0.96%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.42bn
- P/E
- –
- EPS, last 4 quarters
- $-12.71
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.03 to $37.27
- Average volume
- 122.7k
- Previous close
- $31.41
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $53.00, +70.4% from here
Earnings
next estimate $-0.8800Next report
Dec 2025
+50.0%
Mar 2026
–
Jun 2026
–
Sep 2026
-309.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $2.07m | – | – | – |
| Gross profit | $2.07m | – | – | – |
| Operating income | $17.35m | -$3.21m | -$1.77m | -$76.50m |
| Net income | $18.42m | -$3.18m | -$1.75m | -$72.36m |
News
8 latest- Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?Zacks · Oct 27, 2026
- Guggenheim Initiates Coverage of Korsana Biosciences with BuyFintel · Sep 28, 2026
- Cyclerion Soars Over 160% After Announcing Merger With Korsana Biosciences RTTNews · Apr 1, 2026
- Cyclerion Therapeutics (CYCN) Price Target Increased by 100.00% to 8.16Fintel · Feb 25, 2026
- Cyclerion To Advance CYC-126 Into Phase 2 Study For Treatment-resistant Depression RTTNews · Feb 17, 2026
- Cyclerion Expands Partnership With Medsteer; Plans Phase 2 Trial Of CYC-126 In 2H 2026; Stock Up RTTNews · Jan 6, 2026
- Why Is Cyclerion Stock Surging In Pre-market Trade? RTTNews · Sep 24, 2025
- Biotech Stocks Surge After Hours On Trial Updates And Strategic Moves RTTNews · Sep 24, 2025
The company
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company's lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cyclerion.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.